Aamir Badruddin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aamir Badruddin has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Adnan H. Siddiqui
Department of Neurosurgery, State University of New York at Buffalo, Buffalo, New York, USA
1 shared publication - Albert J. Yoo
Neurointervention, Texas Stroke Institute, Plano, Texas, USA
1 shared publication - Alberto Maud
Neurology Texas Tech University of Health Sciences Center El Paso TX United States
1 shared publication - Ameer Hassan
Department of Neurology, Valley Baptist Medical Center - Harlingen, Harlingen, Texas, USA
1 shared publication - Arsida Bajrami
Department of Neurology, Istanbul Aydın University Florya Medical Park Hospital, Istanbul 34295, Turkey
1 shared publication - Arturo Consoli
Department of Diagnostic and Therapeutic Neuroradiology, Hopital Foch, Suresnes, France
1 shared publication
Latest Publications
- Open Access
- 2 December 2023
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 16 (12) , 1220-1227
Primary results from the CLEAR study of a novel stent retriever with drop zone technology
Background Challenges to revascularization of large vessel occlusions (LVOs) persist. Current stent retrievers have limited effectiveness for removing organized thrombi. The NeVa device is a novel stent retriever designed to capture organized thrombi within the scaffold during retrieval. Objective To evaluate the safety and effectiveness of revascularization of acute LVOs with the NeVa device. Methods Prospective, international, multicenter, single-arm, Investigational Device Exemption study to evaluate the performance of the NeVa device in recanalizing LVOs including internal carotid artery, M1/M2 middle cerebral artery, and vertebrobasilar arteries, within 8 hours of onset. Primary endpoint was rate of expanded Treatment in Cerebral Ischemia (eTICI) score 2b–3 within 3 NeVa passes, tested for non-inferiority against a performance goal of 72% with a −10% margin. Additional endpoints included first pass success and 90-day modified Rankin Scale (mRS) score 0–2. Primary composite safety endpoint was 90-day mortality and/or 24-hour symptomatic intracranial hemorrhage (sICH). Results From April 2021 to April 2022, 139 subjects were enrolled at 25 centers. Median National Institutes of Health Stroke Scale (NIHSS) score was 16 (IQR 12–20). In the primary analysis population (n=107), eTICI 2b–3 within 3 NeVa passes occurred in 90.7% (97/107; non-inferiority PConclusions The NeVa device is highly effective and safe for revascularization of LVO strokes and demonstrates superior first pass success compared with a predicate performance goal. Trial registration number NCT04514562.
- 2 December 2023
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 16 (12) , 1220-1227
Open AccessPrimary results from the CLEAR study of a novel stent retriever with drop zone technology
Background Challenges to revascularization of large vessel occlusions (LVOs) persist. Current stent retrievers have limited effectiveness for removing organized thrombi. The NeVa device is a novel stent retriever designed to capture organized thrombi within the scaffold during retrieval. Objective To evaluate the safety and effectiveness of revascularization of acute LVOs with the NeVa device. Methods Prospective, international, multicenter, single-arm, Investigational Device Exemption study to evaluate the performance of the NeVa device in recanalizing LVOs including internal carotid artery, M1/M2 middle cerebral artery, and vertebrobasilar arteries, within 8 hours of onset. Primary endpoint was rate of expanded Treatment in Cerebral Ischemia (eTICI) score 2b–3 within 3 NeVa passes, tested for non-inferiority against a performance goal of 72% with a −10% margin. Additional endpoints included first pass success and 90-day modified Rankin Scale (mRS) score 0–2. Primary composite safety endpoint was 90-day mortality and/or 24-hour symptomatic intracranial hemorrhage (sICH). Results From April 2021 to April 2022, 139 subjects were enrolled at 25 centers. Median National Institutes of Health Stroke Scale (NIHSS) score was 16 (IQR 12–20). In the primary analysis population (n=107), eTICI 2b–3 within 3 NeVa passes occurred in 90.7% (97/107; non-inferiority PConclusions The NeVa device is highly effective and safe for revascularization of LVO strokes and demonstrates superior first pass success compared with a predicate performance goal. Trial registration number NCT04514562.